The basic action mechanism of sodium-glucose cotransporter 2 (SGLT2) inhibitor is to lower the glucose burden by excreting the glucose filtered by the kidney into the urine. Although SGLT2 inhibitors are primarily indicated as glucose-lowering agents, they have a broad range of effects on renal...
Sodium glucose cotransporter 2 inhibitors EMPA-REG OUTCOME [114•] n = 7020 T2D and CVD MACEa Empagliflozin versus placebo 0.86 (0.74–0.99) P < 0.001 non-inferiority, P = 0.04 superiority Genital infections, bone fractures. CANVAS and CANVAS-R [118] n = 4330 T2D/at...
Greco, A. Sodium-Glucose Cotransporter-2 Inhibitors: Elevating Standards in Cardiovascular Secondary Prevention. Am J Cardiovasc Drugs 24, 625–628 (2024). https://doi.org/10.1007/s40256-024-00666-0 Download citation Accepted03 July 2024 Published17 July 2024 Issue DateSeptember 2024 DOIhttps://...
Sodium-glucose cotransporter 2 inhibitors are a class of glucose-lowering drugs, primarily used in patients with type 2 diabetes, which were tested in cardiovascular outcome trials following guidance from international medicines agencies. • Results from cardiovascular outcome trials showed that sodium-gl...
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have now been shown to prevent cardiovascular events, especially hospitalization for heart failure, in three large randomized clinical trials: EMPA-REG OUTCOME, the CANVAS program, and the DECLARE-TIMI58 trial. It is expected, therefore, that SGLT2...
Sodium鈥揼lucose cotransporter 2 inhibitors (SGLT2i), a new drug class initially designed and approved for treatment of diabetes mellitus, have been shown to exert pleiotropic metabolic and direct cardioprotective and nephroprotective effects that extend beyond their glucose-lowering action. These ...
Serum glucoseSodium‐glucose cotransporter‐2 (SGLT‐2)doi:10.1002/9781118682197.ch6Anthony H. BarnettBirmingham Heartlands Hospital University of Birmingham and Heart of England National Health Service Foundation Trust Birmingham, UKJenny GriceLe Prioldy, Bieuzy les Eaux, France...
Joseph M Pappachan,Faculty of Biology, Medicine & Health, The University of Manchester, Manchester M13 9PL, United Kingdom Author contributions: Mondal S contributed to the initial drafting of the work by performing the literature search and interpretation of relevant literature with help from Prama...
Keywords:SGLT2 inhibitors;SGLT2i;Cardiovascular disease;Heart failure;Atherosclerotic cardiovascular disease;Diabetic kidney disease Core Tip:The new antidiabetic medication class sodium glucose cotransporter-2 inhibitors (SGLT-2i) are found to have remarkable cardiovascular (CV) benefits proven by multiple...
Sodium Glucose Cotransporter 2 The SGLT2 localization in the S1 segment of the early proximal tubule and its high capacity for glucose transport fit well with its major role in renal glucose reabsorption. From: Annual Reports in Medicinal Chemistry, 2011 ...